Mazdutide
Also known as: Mazdutide, GLP-1.3, IBI362
Mazdutide (IBI362) is an investigational dual agonist of the GLP-1 and glucagon receptors based on the oxyntomodulin scaffold. It is being studied for weight loss and glycemic control.
Last updated
Mechanism of Action
Mazdutide is a long-acting analog of oxyntomodulin that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). GLP-1R agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety through hypothalamic appetite circuits, while glucagon receptor agonism increases energy expenditure and hepatic lipid utilization. The combined incretin-plus-glucagon signaling is intended to drive greater weight loss and metabolic improvement than GLP-1 activity alone, with fatty-acid acylation extending its half-life for once-weekly dosing.
- Half-life
- Approximately several days, supporting once-weekly dosing
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Promotes substantial weight and body-fat reduction
- Improves glycemic control and lowers HbA1c
- Reduces appetite and food intake via central pathways
- Glucagon-receptor activity may raise energy expenditure
- May improve hepatic steatosis markers
- Once-weekly administration from extended half-life
Potential Side Effects
- Nausea, vomiting, and diarrhea, especially during titration
- Decreased appetite and early satiety
- Possible transient heart-rate increase
- Injection-site reactions
- Risk of hypoglycemia when combined with other glucose-lowering agents
Common Dosing
Clinical trials have evaluated subcutaneous doses in the range of roughly 3-9 mg once weekly with stepwise titration. Provided for research and educational reference only, not as personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy and breastfeeding
- Severe gastrointestinal motility disorders
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Survodutide
Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is administered as a once-weekly subcutaneous injection.
- View
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
2026
- View
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2025
- View
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
2026
- View
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
2023
- View
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
2026